SCHEMBL20183636

SCHEMBL20183636

COC(=O)c1cccc(-c2ccc(CNc3ccc(F)cc3)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
FNTA P49354 1/20 0.57
FNTB P49356 1/20 0.57
PGGT1B P53609 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
HIF1A Q16665 2/20 0.54
PPARA Q07869 3/20 0.52
PLAU P00749 4/20 0.52
CNR2 P34972 1/20 0.52
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
STING1 Q86WV6 1/20 0.50
FFAR1 O14842 1/20 0.48
SENP1 Q9P0U3 1/20 0.47
PLAT P00750 2/20 0.47
PLG P00747 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17158376 0.89 HIF1A (0.64) MEN1KMT2AFNTAFNTBPGGT1B
SCHEMBL20183470 0.87 CA1 (0.69) MEN1KMT2ASMN1; SMN2CA1CA2
SCHEMBL15755382 0.86 HIF1A (0.70) MEN1KMT2ASMN1; SMN2CA1CA2
SCHEMBL7816934 0.85 CA12 (0.64) FNTAFNTBPGGT1BCA1CA2
SCHEMBL15761719 0.83 CA1 (0.75) MEN1KMT2ASMN1; SMN2CA1CA2
SCHEMBL11242935 0.83 CA1 (0.75) MEN1KMT2ASMN1; SMN2CA1CA2
SCHEMBL10243162 0.79 CA12 (0.62) FNTAFNTBPGGT1BCA1CA2
SCHEMBL10243230 0.79 CA12 (0.62) FNTAFNTBPGGT1BCA1CA2
SCHEMBL2571022 0.78 EPHX2 (0.56) MEN1KMT2AFNTAFNTBPGGT1B
SCHEMBL20183490 0.78 PPARA (0.66) MEN1KMT2ASMN1; SMN2HIF1APPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327001-B1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT UNIV DONGGUK IND ACAD COOP (KR) 2022-04-13 EP disclosed
CN-108349875-B Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient 东国大学校产学协力团 2021-08-27 CN disclosed
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2018-08-02 US disclosed
EP-3327001-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT Dongguk University Industry-Academic Cooperation Foundation (KR) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT LTB4R2, CYSLTR2, LTB4R MEN1 3684/4885KMT2A 1026/4885FNTA 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.